CML Flashcards
Name the second generation TKI that is associated with the side effect (can only use each one) Hyperglycemia - Pleural effusions and pulm HTN - Voluminous Diarrhea - Cardiac infarct-
Hyperglycemia - Nilotinib
Pleural effusions - Dasatinib
Voluminous Diarrhea - Bosutinib (also causes thrombocytopenia, elevated LFTs)
Cardiac infarct Nilotinib, (3rd gen: Ponatinib)
In clinical trials of Imatinib stoppage (STIM, TWISTER) what TWO patient features were inclusion criteria for entering the study?
- Patients treated with imatinib x 3 + years ( 5 data points for BCR-ABL transcript)
- Undetectable MRD (MMR log 5 in stim, 4.5 twister) x 2 years
(STIM: CP and AP, TWISTER: CP only)
What percentage of individuals will have durable remission upon stoppage of Imatinib?
▪ 40-50%
o What clinical feature was most predictive of patients who could successfully come off therapy?
▪ Low sokal (Sokal- blast age plt spleen size)
▪ Longer duration of imatinib therapy (>50 mo)
▪ Males
What is different about the activity of ponatinib compared to other TKI
Ponatinib has activity in pts with T315I mutation which causes a structural change of the ATP binding pocket on BCR-ABL. This mutation causes resistance to all of the other TKIs.
For each log reduction (1-5), list % the BCR-ABL transcript that is detectable. What is MMR, DMR and CMR?
Log 1=10% EMR Log 2=1% Log 3=0.1% MMR Log 4=0.01% DMR Log 4.5=0.0032% Log 5 = 0.001% CMR
In which CML patients would you consider transplant?
- Intolerant to all TKIs
- Blast phase (ideally get into CR with TKI or chemo)
- Patients relapsing with a T315I mutation because response to ponatinib is usually short.
- Accelerated phase with poor response to TKI
What is omacetaxine?
Protein synthesis inhibitor that has demonstrated activity in CML in chronic phase with a T315I mutation, or failure of 2 previous TKIs.
SC BID x 14days q28 days
SE: adverse events included hematological toxicity (thrombocytopenia, anemia, neutropenia, lymphopenia), gastrointestinal (diarrhea, nausea) toxicity, weakness and fatigue, as well as reaction at the injection site.
What are the 3 major break point mutations seen in CML?
- p190BCR-ABL1 (resulting from fusion at the minor breakpoint or m-BCR site)
- p210BCR-ABL1 gene product (resulting from fusion at the major breakpoint or M-BCR site)
- p230BCR-ABL1 (resulting from fusion at the micro breakpoint or mu-BCR site)
*p210 is most common.
What is the median survival for blast phase CML? (in the TKI era)
bad! 7-11 months
What is the criteria for complete hematological response (CHR) in CML?
- resolution of symptoms/signs of the disease, including palpable splenomegaly
- leukocytes <10 × 109/
- Normal differential (absence of immaturity (myelocytes, pro-myelocytes, blasts, etc.)
- platelets <450 × 109/L
How many Ph-positive metaphases are seen in: minor, minimal, major and complete cytogenetic response?
Based on marrow cyto: complete (no Ph+ cells). major (1 to 35 percent) minor (36 to 65 percent) minimal (66 to 95 percent) no response (>95 percent)
5 unique toxicities of Nilotinib
- Hyperglycemia
- Hyperlipidemia
- Qtc prolongation
- Increased lipase
- Increased stroke risk
- increased CAD
- Increased PVD
*extreme caution in individuals with diabetes mellitus, cardiovascular disease, or metabolic syndrome
ENESTnd compared nilotinib (either 300mg or 400mg PO BID to Imantinib 400mg PO daily). What were the significant end points
Nilotinib was superior in terms of:
- EMR at 3 mos, CCyR at 12 months
- Time to progression to AP or blast phase
- MMR, MR
- Comparable PFS and OS (approximately 95 percent OS after two years) (300mg PO BID)
*Nilotinib 400 mg twice daily was superior to imatinib with regard to OS, PFS, EFS, and progression, but this dose was associated with unacceptable levels of CV toxicity.
Other that T315I, name 3 other markers of TKI resistance in CML.
- F317L
- F359V/C/I
- E255K/V
- V299L
- M244V
Major side effects of potnatinib (BB warnings):
- Vascular events: MI, stroke, stenosis of large arterial vessels of the brain, severe PVD
- VTE
- Heart failure
- Hepatoxicity
Others: HTN, rash, thrombocytopenia, abdominal pain.
What are the arguments for choosing 2nd generation TKI upfront for CP CML instead of imatinib?
- Quicker MMR and MR4.5
- Less mutation/resistance development
- Decreased rates of progression to AP, BP
But no change in PFS or OS